Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (pentasa) in the maintenance treatment of ulcerative colitis

European Journal of Gastroenterology and Hepatology

Volumn 7, Issue 11, 1995, Pages 1025-1030

  Fockens, Paul ^a   Mulder, Chris J J ^b   Tytgat, Guido N J ^a   Blok, Paul ^c   Ferwerda, Jaap ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d Kennemer Hospital   (Netherlands)

Author keywords

Maintenance treatment; Mesalazine; Side effects; Ulcerative colitis

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUSTAINED RELEASE PREPARATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; SIGMOIDOSCOPY; TIME FACTORS;

EID: 9044250095     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-199511000-00003     Document Type: Article

References (24)

1. Azad Khan AK, Howes DT, Piris J, Truelove SC: Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980, 21:232-240.
2. Taffet SL, Das KM: Sulfasalazine, adverse effects and desensi-tization. Dig Dis Sci 1983, 28:833-842.
3. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet1977, ii:892-895.
4. Klotz U: Therapy of inflammatory bowel disease using new 5-ASA compounds: An introduction. Con J Gastroenterol 1989, 3:82-84.
5. Mulder CJJ, Tytgat GNJ, Dekker W: Pentasa in lieu of sulfasalazine. Ann Intern Med1988, 108:911-912.
6. Law R, Hanauer S, Rick G, Safdi M, Rogers A, Wruble L, Gal-braith H, et al.:Multicenter, open-label, longterm safety study of oral Pentasa (controlled-release mesalamine) in Crohn’s disease [abstract]. Gastroenterology1990, 98:A185.
7. Schroeder KW, Tremaine WJ, llslrup DM: Coated oral 5-aminosalicylic acid therapy for mild to moderate active ulcerative colitis; a randomized study. N Engl I Med1987, 317:1625-1629.
8. Lauritsen K, Staerk Laursen L, Bukhave K, Rask-Madsen J: Long-term olsalazine treatment: Pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn’s disease. Gut1988, 29:974-982.
9. Rachmilewitz D: Coated mesalazin (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ1989, 298:82-86.
10. Riley SA, Mani V, Goodman MJ, Herd ME, Dult S, Turn-berg LA: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988, 94:1383-1389.
11. Mulder CJJ, Tytgat GNJ, Weterman IT, Dekker W, Blok P, Schrijver M, et al.:Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazin in remission maintenance in ulcerative colitis. Gastroenterology1988, 95:1449-1453.
12. Rutgeerts P: Comparative efficacy of coated oral 5-aminosalicylic acid (Claversal) and sulphalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther1989, 3:183-191.
13. Hanauer S, Beshears L, Wilkinson C, Schwartz J, Roufail W, Robinson M, etal.: And The Pentasa Study Group: Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa) [abstract]. Gastroenterology1990, 98:A174.
14. Hanauer S, Belker M, Gitnick G, Krawitt E, Roufail W, Wruble L, et al. and The Pentasa Study Group: Multicenter, placebo-controlled, dose-ranging study of oral Pentasa (controlled-release mesalamine) for active Crohn’s disease: Preliminary results [abstract]. Gastroenterology1990, 98:A173.
15. Singleton J, Gitnick G, Hanauer S, Krawilt E, Robinson M, Roufail W, et al.:Response of Crohn’s disease to oral Pentasa (controlled-release mesalamine) as a function of disease location and prior therapy: Results of a multi-center study [abstract]. Gastroenterology1991, 100:A251.
16. Gionchetti P, Campieri M, Beluuzi A, Brignola C, Tampieri M, lannone P, etal:.Pentasa in maintenance treatment of ulcerative colitis. Gastroenterology1990, 98:251.
17. Hanauer SB: Medical therapy of ulcerative colitis. Lancet 1993, 342:412-417.
18. De Dombal FT, Dew MJ, Hanauer SB, Miglioli M, Paoluzi P, Rachmilewitz D, et al:.Towards an optimal dosage of oral-5-ASA in ulcerative colitis. Gastroenterol Int1992, 5:155-161.
19. Tytgat GNJ, van Olffen G: Role of ileocolonoscopy in diagnosis and follow-up of inflammatory bowel disease. Acta Endosc1983, 13:245-253.
20. Van der Heide H, Van de Brandt-Grädel V, Tytgat GNJ, Endert E, Schipper M, Dekker W: Comparison of beclomethasonedipro-pionate and prednisolone-21-phosphate enemas in distal ulcerative colitis. J Clin Gastroenterol 1988, 10:169-172.
21. Mulder CJJ, Tytgat GNJ, Wiltink EHH, Houthoff HJ: Comparison of 5-aminosalicylic acid (3g) and prednisone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. Scand J Gastroenterol 1988, 23:1003-1008.
22. Ruf-Ballauf W, Hofstadter F, Krentz K: Acute interstitial nephritis through 5-aminosalicylic acid? [in German]. Internist1989, 30:262-264.
23. Polok M, Stachowski J, Kruis W, Helmchen U, Baldamus CA: Induction of chronic tubulointerstitial nephritits (TIN) by 5-aminosalicylic acid (5-ASA) in chronic inflammatory bowel disease (CIBD).; Am Soc Nephrol 1991, 2:242.
24. De Francis R, Vecchi M, Carpinelli L, McUcci G, Torgano G: Comparison of the efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis: A meta-analysis. Eur J Gastroenterol Hepatol 1993, 5:505-510.